Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
34 /100
COMPONENT-LIMITED
Score updated Sep 12, 2026

RANI — Rani Therapeutics Holdings, Inc. Dilution Risk Tracker

Track RANI dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track RANI — Get alerts when the score changes →

As of September 12, 2026, Rani Therapeutics Holdings, Inc. (RANI) has a DilutionWatch DilutionScore of 34/100, rated MEDIUM dilution risk. This is a component-limited score because one or more material inputs are unavailable or not applicable. Rani Therapeutics Holdings, Inc. has a market capitalization of $130.72M, 21.41M shares outstanding, 75 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
52
💰 Cash Runway
10
📊Float Risk
⚠️ Warrant Exposure
40
🔄 Convertible Debt
15

Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
model est. 27%
🔄 Reverse Split model est. 55%
• 50-day avg $0.95 below $1 exchange minimum
🔔 Track RANI — Get forecast alerts →

Market Data

Market Cap$130.72M
Shares Outstanding21.41M
FloatN/A
Cash$103.37M
Debt$3.94M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore34/100DilutionWatch score record
Shares Outstanding21.41MVerified float table or market cache
Public FloatNot availableVerified float table or market cache
Market Cap$130.72MMarket data cache
Cash Runway34.3 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 2.

Recent SEC source mix: XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 1.3% shares (2026Q1 vs prior)
75 institutional holders · 49.36M shares
#1 VANGUARD CAPITAL MANAGEMENT LLC 9.25M shares
#2 RA CAPITAL MANAGEMENT, L.P. 8.50M shares
#3 SAMSARA BIOCAPITAL, LLC 8.50M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest6.39M
Days to Cover8.1
% of FloatN/A
FINRA data as of Aug 31, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31
xbrl XBRL CONVERTIBLE 2020-12-31
Full SEC filing analysis available with free account

Recent News

No recent news

Factual RANI Dilution Snapshot

Rani Therapeutics Holdings, Inc. (RANI) has a DilutionScore of 34/100, rated Medium dilution risk. Score date: September 12, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track RANI Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking RANI — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,348+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations

Score Coverage Note

More Research for RANI
RANI FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.